Capital International Investors
BHVN

Capital International Investors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Capital International Investors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,525,202
Closed -$231M – 453
2022
Q3 		$231M Sell
1,525,202
-163
-0% -$24.2K 0.07% 224
2022
Q2 		$222M Sell
1,525,365
-1,157,551
-43% -$148M 0.06% 237
2022
Q1 		$318M Sell
2,682,916
-2,322,910
-46% -$290M 0.07% 219
2021
Q4 		$690M Sell
5,005,826
-359,239
-7% -$45.7M 0.15% 145
2021
Q3 		$745M Sell
5,365,065
-275,997
-5% -$34.5M 0.17% 133
2021
Q2 		$548M Buy
5,641,062
+62,830
+1% +$5.1M 0.13% 162
2021
Q1 		$381M Buy
5,578,232
+247,254
+5% +$20M 0.1% 185
2020
Q4 		$457M Sell
5,330,978
-416,207
-7% -$35.3M 0.12% 163
2020
Q3 		$374M Sell
5,747,185
-262,830
-4% -$17.2M 0.12% 167
2020
Q2 		$439M Buy
6,010,015
+6,280
+0.1% +$334K 0.14% 137
2020
Q1 		$204M Buy
6,003,735
+3,082,031
+105% +$141M 0.08% 171
2019
Q4 		$159M Buy
2,921,704
+1,508,804
+107% +$74.7M 0.05% 207
2019
Q3 		$58.9M Buy
1,412,900
+20,000
+1% +$845K 0.02% 259
2019
Q2 		$61M Buy
+1,392,900
New +$78.5M 0.02% 269

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Capital International Investors's BHVN Position: Q4 2022 in Review

Capital International Investors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,525,202 shares — an estimated $231M sold.

Capital International Investors first reported a position in BHVN in Q2 2019 and held it in 14 quarters. The position peaked at $745M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Capital International Investors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Capital International Investors sold 1,525,202 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $231M.
  • Capital International Investors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 14 quarters.
  • Capital International Investors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $745M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Capital International Investors's 13F filing for Q4 2022, filed 14 Feb 2023.